Promis Neurosciences Inc (PMN)

$0.43 +0.00 (0.58%)
Market Cap 23.22M
Revenue (ttm) 0.00
Net Income (ttm) 2.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 338,900
Avg Vol 1,713,610
Day's Range N/A - N/A
Shares Out 53.81M
Stochastic %K 22%
Beta -0.17
Analysts Strong Sell
Price Target $6.10

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer'...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 847 6898
Fax: 416 847 6899
Address:
1920 Yonge Street, Suite 200, Toronto, Canada
asymmetricvalue
asymmetricvalue Oct. 23 at 1:37 PM
$PMN VOTE NO
1 · Reply
BKLYN_Bull
BKLYN_Bull Oct. 20 at 3:37 PM
$PMN vote NO
1 · Reply
asymmetricvalue
asymmetricvalue Oct. 20 at 2:38 AM
$PMN If you own shares, vote NO to the reverse split. Make them do the work to raise the price. It should not come out of retail’s pocket. They will simply dilute us after the fact. This company has real potential with very promis-ing pipeline candidates. It should succeed, but we should also.
1 · Reply
cantrder72
cantrder72 Oct. 17 at 5:32 PM
$PMN jump
0 · Reply
YungnredE
YungnredE Oct. 15 at 2:37 PM
$IVF $PMN You are the last of the garbage stocks that hasn't had a green day. If GNPX can move there's still hope for these 2.
0 · Reply
Geessus
Geessus Oct. 12 at 3:51 AM
$PMN I ain’t no scientist but I do have baggage let me drop it here..
0 · Reply
Tradermelvin
Tradermelvin Oct. 11 at 5:19 PM
$PMN Price up steady and talk of insider buying
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 11:36 PM
Keep a close watch on CMCT! $TRIB $WINT $ZBIO $PMN _
0 · Reply
Misterx69
Misterx69 Oct. 8 at 3:29 PM
$PMN How many shares do you have? I have 15k but I'd like to increase now.
1 · Reply
SayZero
SayZero Oct. 8 at 2:21 PM
$PMN I Banked on the ask. It went through at a sec moment.
0 · Reply
Latest News on PMN
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Oct 22, 2025, 7:30 AM EDT - 3 days ago

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

Sep 3, 2025, 7:00 AM EDT - 7 weeks ago

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

Aug 13, 2025, 7:00 AM EDT - 2 months ago

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

Jul 29, 2025, 8:00 AM EDT - 3 months ago

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

ProMIS Neurosciences Announces Private Placement Financing

Jul 28, 2025, 7:00 AM EDT - 3 months ago

ProMIS Neurosciences Announces Private Placement Financing

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

Jul 21, 2025, 8:00 AM EDT - 3 months ago

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 17, 2025, 7:00 AM EDT - 4 months ago

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 5 months ago

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Mar 31, 2025, 7:00 AM EDT - 7 months ago

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Mar 24, 2025, 7:00 AM EDT - 7 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

Mar 13, 2025, 7:00 AM EDT - 8 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

Mar 11, 2025, 7:30 AM EDT - 8 months ago

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

Feb 25, 2025, 7:00 AM EST - 8 months ago

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 7:30 AM EST - 9 months ago

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

ProMIS Neurosciences Issues Letter to Shareholders

Jan 13, 2025, 10:30 AM EST - 10 months ago

ProMIS Neurosciences Issues Letter to Shareholders

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Nov 14, 2024, 9:15 AM EST - 1 year ago

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

Sep 12, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

Aug 1, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

Jul 30, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Jul 26, 2024, 8:35 AM EDT - 1 year ago

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

Jul 26, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

May 14, 2024, 4:01 PM EDT - 1 year ago

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Apr 30, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Apr 9, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

Apr 4, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Apr 1, 2024, 4:15 PM EDT - 1 year ago

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Mar 11, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Feb 22, 2024, 7:00 AM EST - 1 year ago

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Jan 22, 2024, 7:00 AM EST - 1 year ago

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

ProMIS Neurosciences, Inc. Announces Leadership Transition

Jan 3, 2024, 7:00 AM EST - 1 year ago

ProMIS Neurosciences, Inc. Announces Leadership Transition

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Dec 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Announces Publication on Novel Target for ALS

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

Nov 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Nov 14, 2023, 4:30 PM EST - 2 years ago

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

Sep 8, 2023, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 12:18 PM EDT - 2 years ago

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

Aug 21, 2023, 4:12 PM EDT - 2 years ago

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

Aug 14, 2023, 5:33 PM EDT - 2 years ago

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

Jul 17, 2023, 7:00 AM EDT - 2 years ago

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

ProMIS Announces Completion of Continuance

Jul 14, 2023, 7:45 AM EDT - 2 years ago

ProMIS Announces Completion of Continuance

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

Jul 10, 2023, 7:55 AM EDT - 2 years ago

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

Jun 30, 2023, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

Jun 29, 2023, 8:00 AM EDT - 2 years ago

CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

May 15, 2023, 5:00 PM EDT - 2 years ago

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's Disease

May 8, 2023, 9:00 AM EDT - 2 years ago

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's Disease

Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer's Disease

Apr 25, 2023, 5:00 PM EDT - 2 years ago

Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer's Disease

ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer's Disease and ALS at American Academy of Neurology Annual Meeting

Apr 24, 2023, 7:30 AM EDT - 2 years ago

ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer's Disease and ALS at American Academy of Neurology Annual Meeting

ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

Apr 10, 2023, 7:30 AM EDT - 2 years ago

ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

Mar 29, 2023, 8:30 AM EDT - 2 years ago

Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

asymmetricvalue
asymmetricvalue Oct. 23 at 1:37 PM
$PMN VOTE NO
1 · Reply
BKLYN_Bull
BKLYN_Bull Oct. 20 at 3:37 PM
$PMN vote NO
1 · Reply
asymmetricvalue
asymmetricvalue Oct. 20 at 2:38 AM
$PMN If you own shares, vote NO to the reverse split. Make them do the work to raise the price. It should not come out of retail’s pocket. They will simply dilute us after the fact. This company has real potential with very promis-ing pipeline candidates. It should succeed, but we should also.
1 · Reply
cantrder72
cantrder72 Oct. 17 at 5:32 PM
$PMN jump
0 · Reply
YungnredE
YungnredE Oct. 15 at 2:37 PM
$IVF $PMN You are the last of the garbage stocks that hasn't had a green day. If GNPX can move there's still hope for these 2.
0 · Reply
Geessus
Geessus Oct. 12 at 3:51 AM
$PMN I ain’t no scientist but I do have baggage let me drop it here..
0 · Reply
Tradermelvin
Tradermelvin Oct. 11 at 5:19 PM
$PMN Price up steady and talk of insider buying
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 11:36 PM
Keep a close watch on CMCT! $TRIB $WINT $ZBIO $PMN _
0 · Reply
Misterx69
Misterx69 Oct. 8 at 3:29 PM
$PMN How many shares do you have? I have 15k but I'd like to increase now.
1 · Reply
SayZero
SayZero Oct. 8 at 2:21 PM
$PMN I Banked on the ask. It went through at a sec moment.
0 · Reply
Cellsci
Cellsci Oct. 7 at 3:41 PM
$PMN I encourage all to review Dr.Wisharts .This is cutting edge! We will be rewarded
1 · Reply
Cellsci
Cellsci Oct. 7 at 3:34 PM
$PMN Management Team :: ProMIS Neurosciences, Inc. (PMN) https://www.promisneurosciences.com/about/management-team
0 · Reply
nrgzr2
nrgzr2 Oct. 7 at 3:06 PM
$PMN In Barrons Daily this morning they mention that stocks are liking AI Deals. This could be applicable to a message on the stockhouse dot com PMN bullboard by retiredcop that mentions that Dr Neil Cashman just signed a new contract. Dr Neil Cashman is the CMO of PMN and the creator of PMNs AI generated Intellectual Property for creating monoclonal antibodies to attach to the best epitope to treat neurodegenerative diseases without causing ARIA. ARIA has caused failures to big Pharma in their pursuit in treatments for neurodegenerative diseases.
1 · Reply
SayZero
SayZero Oct. 7 at 2:49 PM
$PMN Waiting.....
0 · Reply
Misterx69
Misterx69 Oct. 7 at 2:19 PM
$PMN increasing volume
0 · Reply
MH2024
MH2024 Oct. 7 at 1:53 PM
$PMN Let’s Go!!
0 · Reply
Misterx69
Misterx69 Oct. 7 at 1:53 PM
$PMN
0 · Reply
ridethewaves3
ridethewaves3 Oct. 7 at 11:05 AM
$PMN
0 · Reply
Drainomight
Drainomight Oct. 7 at 8:46 AM
$PMN
0 · Reply
nrgzr2
nrgzr2 Oct. 6 at 9:31 PM
$PMN
0 · Reply
Drainomight
Drainomight Oct. 6 at 5:20 PM
$PMN we got a code p purchase of 30,392 shares insider….
1 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 6 at 4:42 PM
💊 🚀 $PMN up ⬆️42.38% since our entry $0.3990 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply